PI-QUAL对MRI-TRUS融合活检人群中PI-RADS及癌症检出率的影响
本研究纳入50例接受经直肠超声引导MRI融合活检的患者的前列腺多参数MRI,由两名放射科医师独立评分PI-QUAL及序列诊断质量。PI-QUAL读者间一致性中等(kappa 0.51),PI-RADS分类一致性很好(kappa 0.86);PI-QUAL>3与≤3的总体诊断性能无显著差异(p=0.552;AUC 0.805和0.839),但PI-QUAL≤3时前列腺癌患病率显著更低(16.7% vs. 30.2%,p=0.008)。
要点
- PI-QUAL评分读者间一致性中等(kappa 0.51),序列诊断质量一致性差至一般(kappa 0.19–0.29)。
- PI-RADS分类读者间一致性很好(kappa 0.86),不受PI-QUAL评分显著影响。
- PI-QUAL≤3时前列腺癌患病率显著低于>3(16.7% vs. 30.2%,p=0.008)。
核心结论
- PI-QUAL对计划行MRI-TRUS融合活检患者的PI-RADS诊断性能影响有限,但低PI-QUAL类别中癌症患病率更低,提示成像质量低时存在假阳性转诊和不必要活检的风险。
研究设计与样本
- 纳入50例接受经直肠超声引导MRI融合活检患者的前列腺多参数MRI(T2加权、DWI和DCE),两名放射科医师独立分配PI-QUAL评分并评估各序列诊断质量,PI-RADS分类按每前列腺六个区域(左/右:基底/中部腺体/尖部)分配。
诊断标准与关键数值
- 在274个诊断区域中,恶性率为62.7%(临床显著前列腺癌,ISUP≥2,占22.5%);PI-QUAL>3与≤3的总体诊断性能无显著差异(p=0.552;AUC分别为0.805和0.839)。
临床应用与阅片要点
- PI-QUAL评分≤3时前列腺癌患病率显著更低(16.7% vs. 30.2%,p=0.008),提示成像质量低时存在假阳性转诊和不必要活检的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To test the inter-reader agreement of the Prostate Imaging Quality (PI-QUAL) score for multiparametric prostate MRI and its impact on diagnostic performance in an MRI-ultrasound fusion biopsy population.
PATIENTS AND METHODS: Pre-biopsy multiparametric (T2-weighted, DWI, and DCE) prostate MRIs (mpMRI) of 50 patients undergoing transrectal ultrasound-guided MRI-fusion (MRI-TRUS) biopsy were included. Two radiologists independently assigned a PI-QUAL score to each patient and assessed the diagnostic quality of individual sequences. PI-RADS categories were assigned to six regions per prostate (left and right: base/mid-glandular/apex). Inter-reader agreement was calculated using Cohen's kappa and diagnostic performance was compared by the area under the receiver operating characteristics curve (AUC).
RESULTS: In 274 diagnostic areas, the malignancy rate was 62.7% (22.5% clinically significant prostate cancer, ISUP ≥ 2). Inter-reader agreement for the diagnostic quality was poor for T2w (kappa 0.19), fair for DWI and DCE (kappa 0.23 and 0.29) and moderate for PI-QUAL (kappa 0.51). For PI-RADS category assignments, inter-reader agreement was very good (kappa 0.86). Overall diagnostic performance did not differ between studies with a PI-QUAL score > 3 compared to a score ≤ 3 (p = 0.552; AUC 0.805 and 0.839). However, the prevalence of prostate cancer was significantly lower when the PI-QUAL score was ≤ 3 (16.7% vs. 30.2%, p = 0.008).
CONCLUSION: PI-QUAL has only a limited impact on PI-RADS diagnostic performance in patients scheduled for MRI-TRUS fusion biopsy. However, the lower cancer prevalence in the lower PI-QUAL categories points out a risk of false-positive referrals and unnecessary biopsies if prostate imaging quality is low.
引用
- Pötsch, Rainer, Clauser, et al. Impact of PI-QUAL on PI-RADS and cancer yield in an MRI-TRUS fusion biopsy population. Eur J Radiol. 2022. PMID: 35803101. doi:10.1016/j.ejrad.2022.110431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。